胶原蛋白价格战开打，同功效产品价差三四倍

Core Viewpoint - The medical beauty injection market is experiencing unprecedented differentiation, with high-end collagen products priced around ten thousand yuan and domestic hyaluronic acid rapidly capturing the mid-to-low-end market with over 70% market share. Domestic collagen manufacturers are caught in a strategic dilemma between engaging in price wars or restructuring their value systems [1][2]. Market Growth and Dynamics - The retail market size for medical beauty injections in China has grown from 25.7 billion yuan in 2018 to 67 billion yuan in 2023, with a compound annual growth rate (CAGR) of 21.1%, and is expected to exceed 147 billion yuan by 2027, driven by technological iterations and upgraded consumer demand for products like hyaluronic acid and collagen [1][2]. Competitive Landscape - The collagen market is characterized by a "strong at both ends, weak in the middle" structure, where imported brands dominate the high-end market with prices between 8,000 to 12,000 yuan, while numerous new entrants flood the mid-to-low-end market with prices dropping below 1,000 yuan [6][11]. Pricing and Quality Issues - The price war has led to chaotic pricing in the market, with price differences for similar products reaching three to four times. Many institutions use low-priced products for customer acquisition, resulting in poor satisfaction and damage to brand reputation [2][7]. Technological Competition - High-quality animal collagen production costs range from 800 to 1,200 yuan, while recombinant collagen can be produced for under 200 yuan, explaining the presence of low-priced products in the market. The market is currently undergoing a reassessment of collagen products [8][10]. R&D and Investment Trends - Companies like Faiman Biotech are investing significantly in R&D, with annual R&D expenditures constituting 15% to 18% of revenue, surpassing the industry average of 8%. This investment is expected to translate into technological advantages [12][16]. Regulatory and Market Changes - The regulatory environment is tightening, with increased inspections leading to production halts for non-compliant companies. The capital market is shifting focus towards companies with core technological patents and comprehensive quality control systems [15][16]. Future Outlook - The industry is expected to shift from price sensitivity to value assessment, with a need for a comprehensive evaluation system that includes raw material sourcing, production processes, and long-term safety data. The market is anticipated to stabilize as consumer awareness of safety and quality increases [15][17].